Mouse methylome studies SRP063093 Track Settings
 
Acute loss of TET function results in aggressive myeloid cancer in mice [WGBS] [LSK]

Track collection: Mouse methylome studies

+  All tracks in this collection (596)

Maximum display mode:       Reset to defaults   
Select views (Help):
CpG reads ▾       HMR       CpG methylation ▾       PMD       AMR      
Select subtracks by views and experiment:
 All views CpG reads  HMR  CpG methylation  PMD  AMR 
experiment
SRX1177958 
SRX1177959 
SRX1177960 
SRX1177961 
SRX1177962 
SRX1177963 
List subtracks: only selected/visible    all    ()
  experiment↓1 views↓2   Track Name↓3  
hide
 Configure
 SRX1177958  CpG reads  LSK / SRX1177958 (CpG reads)   Schema 
hide
 SRX1177958  HMR  LSK / SRX1177958 (HMR)   Schema 
hide
 Configure
 SRX1177958  CpG methylation  LSK / SRX1177958 (CpG methylation)   Schema 
hide
 SRX1177958  PMD  LSK / SRX1177958 (PMD)   Schema 
hide
 SRX1177958  AMR  LSK / SRX1177958 (AMR)   Schema 
hide
 Configure
 SRX1177959  CpG reads  LSK / SRX1177959 (CpG reads)   Schema 
hide
 SRX1177959  HMR  LSK / SRX1177959 (HMR)   Schema 
hide
 Configure
 SRX1177959  CpG methylation  LSK / SRX1177959 (CpG methylation)   Schema 
hide
 SRX1177959  PMD  LSK / SRX1177959 (PMD)   Schema 
hide
 SRX1177959  AMR  LSK / SRX1177959 (AMR)   Schema 
hide
 SRX1177960  HMR  LSK / SRX1177960 (HMR)   Schema 
hide
 Configure
 SRX1177960  CpG reads  LSK / SRX1177960 (CpG reads)   Schema 
hide
 Configure
 SRX1177960  CpG methylation  LSK / SRX1177960 (CpG methylation)   Schema 
hide
 SRX1177960  PMD  LSK / SRX1177960 (PMD)   Schema 
hide
 SRX1177960  AMR  LSK / SRX1177960 (AMR)   Schema 
hide
 SRX1177961  HMR  LSK / SRX1177961 (HMR)   Schema 
hide
 SRX1177961  PMD  LSK / SRX1177961 (PMD)   Schema 
hide
 SRX1177961  AMR  LSK / SRX1177961 (AMR)   Schema 
hide
 Configure
 SRX1177961  CpG reads  LSK / SRX1177961 (CpG reads)   Schema 
hide
 Configure
 SRX1177961  CpG methylation  LSK / SRX1177961 (CpG methylation)   Schema 
hide
 Configure
 SRX1177962  CpG reads  LSK / SRX1177962 (CpG reads)   Schema 
hide
 SRX1177962  HMR  LSK / SRX1177962 (HMR)   Schema 
hide
 Configure
 SRX1177962  CpG methylation  LSK / SRX1177962 (CpG methylation)   Schema 
hide
 SRX1177962  PMD  LSK / SRX1177962 (PMD)   Schema 
hide
 SRX1177962  AMR  LSK / SRX1177962 (AMR)   Schema 
hide
 Configure
 SRX1177963  CpG reads  LSK / SRX1177963 (CpG reads)   Schema 
hide
 SRX1177963  HMR  LSK / SRX1177963 (HMR)   Schema 
hide
 Configure
 SRX1177963  CpG methylation  LSK / SRX1177963 (CpG methylation)   Schema 
hide
 SRX1177963  PMD  LSK / SRX1177963 (PMD)   Schema 
hide
 SRX1177963  AMR  LSK / SRX1177963 (AMR)   Schema 
    

Study title: Acute loss of TET function results in aggressive myeloid cancer in mice [WGBS]
SRA: SRP063093
GEO: GSE72629
Pubmed: not found

Experiment Label Methylation Coverage HMRs HMR size AMRs AMR size PMDs PMD size Conversion Details
SRX1177958 LSK 0.788 2.7 33120 1331.0 31 1096.2 264 47922.2 0.995 title: GSM1866966 WGBS seq WT LSK BR1, Mus musculus, Bisulfite-Seq; source_name: wild type LSK cells biological replicate (BR) 1; cell_type: LSK cells; genotype: Wild Type
SRX1177959 LSK 0.784 2.8 34062 1289.9 29 949.6 467 36509.4 0.996 title: GSM1866967 WGBS seq WT LSK BR2, Mus musculus, Bisulfite-Seq; source_name: wild type LSK cells biological replicate (BR) 2; cell_type: LSK cells; genotype: Wild Type
SRX1177960 LSK 0.788 2.7 33533 1322.7 26 967.5 464 38314.0 0.996 title: GSM1866968 WGBS seq WT LSK BR3, Mus musculus, Bisulfite-Seq; source_name: wild type LSK cells biological replicate (BR) 3; cell_type: LSK cells; genotype: Wild Type
SRX1177961 LSK 0.800 3.0 29334 1309.2 22 994.8 331 32180.8 0.997 title: GSM1866969 WGBS seq DKO LSK BR1, Mus musculus, Bisulfite-Seq; source_name: Tet2/Tet3 DKO LSK cells biological replicate (BR) 1; cell_type: LSK cells; genotype: Tet2/3 DKO mice
SRX1177962 LSK 0.788 3.7 30521 1242.5 58 963.4 342 29135.4 0.995 title: GSM1866970 WGBS seq DKO LSK BR2, Mus musculus, Bisulfite-Seq; source_name: Tet2/Tet3 DKO LSK cells biological replicate (BR) 2; cell_type: LSK cells; genotype: Tet2/3 DKO mice
SRX1177963 LSK 0.804 3.2 31400 1257.2 54 953.5 417 29767.2 0.995 title: GSM1866971 WGBS seq DKO LSK BR3, Mus musculus, Bisulfite-Seq; source_name: Tet2/Tet3 DKO LSK cells biological replicate (BR) 3; cell_type: LSK cells; genotype: Tet2/3 DKO mice

Methods

All analysis was done using a bisulfite sequnecing data analysis pipeline DNMTools developed in the Smith lab at USC.

Mapping reads from bisulfite sequencing: Bisulfite treated reads are mapped to the genomes with the abismal program. Input reads are filtered by their quality, and adapter sequences in the 3' end of reads are trimmed. This is done with cutadapt. Uniquely mapped reads with mismatches/indels below given threshold are retained. For pair-end reads, if the two mates overlap, the overlapping part of the mate with lower quality is discarded. After mapping, we use the format command in dnmtools to merge mates for paired-end reads. We use the dnmtools uniq command to randomly select one from multiple reads mapped exactly to the same location. Without random oligos as UMIs, this is our best indication of PCR duplicates.

Estimating methylation levels: After reads are mapped and filtered, the dnmtools counts command is used to obtain read coverage and estimate methylation levels at individual cytosine sites. We count the number of methylated reads (those containing a C) and the number of unmethylated reads (those containing a T) at each nucleotide in a mapped read that corresponds to a cytosine in the reference genome. The methylation level of that cytosine is estimated as the ratio of methylated to total reads covering that cytosine. For cytosines in the symmetric CpG sequence context, reads from the both strands are collapsed to give a single estimate. Very rarely do the levels differ between strands (typically only if there has been a substitution, as in a somatic mutation), and this approach gives a better estimate.

Bisulfite conversion rate: The bisulfite conversion rate for an experiment is estimated with the dnmtools bsrate command, which computes the fraction of successfully converted nucleotides in reads (those read out as Ts) among all nucleotides in the reads mapped that map over cytosines in the reference genome. This is done either using a spike-in (e.g., lambda), the mitochondrial DNA, or the nuclear genome. In the latter case, only non-CpG sites are used. While this latter approach can be impacted by non-CpG cytosine methylation, in practice it never amounts to much.

Identifying hypomethylated regions (HMRs): In most mammalian cells, the majority of the genome has high methylation, and regions of low methylation are typically the interesting features. (This seems to be true for essentially all healthy differentiated cell types, but not cells of very early embryogenesis, various germ cells and precursors, and placental lineage cells.) These are valleys of low methylation are called hypomethylated regions (HMR) for historical reasons. To identify the HMRs, we use the dnmtools hmr command, which uses a statistical model that accounts for both the methylation level fluctations and the varying amounts of data available at each CpG site.

Partially methylated domains: Partially methylated domains are large genomic regions showing partial methylation observed in immortalized cell lines and cancerous cells. The pmd program is used to identify PMDs.

Allele-specific methylation: Allele-Specific methylated regions refers to regions where the parental allele is differentially methylated compared to the maternal allele. The program allelic is used to compute allele-specific methylation score can be computed for each CpG site by testing the linkage between methylation status of adjacent reads, and the program amrfinder is used to identify regions with allele-specific methylation.

For more detailed description of the methods of each step, please refer to the DNMTools documentation.